Sanoculis’ MINT® Glaucoma Treatment Secures CE Mark Approval
A Breakthrough in Glaucoma Care
Sanoculis has reached a major milestone after receiving CE Mark approval for its MINT® Glaucoma Treatment. This new technology introduces a minimally invasive way to manage glaucoma, helping reduce intraocular pressure (IOP) while protecting vision.
Glaucoma remains one of the leading causes of irreversible blindness worldwide. Traditional treatments—such as eye drops, laser therapy, and surgery—can be effective but often come with limitations. MINT® offers a simpler and potentially safer alternative for both patients and eye care professionals.
What Is the MINT® Glaucoma Treatment?
The MINT® (Minimally Invasive Nano-Tube) is a small implant designed to improve the natural drainage of fluid in the eye. By enhancing outflow, it helps control IOP, which is critical in slowing glaucoma progression.
Key Features
-
Minimally invasive procedure – Less surgical trauma and faster recovery
-
Biocompatible materials – Designed for long-term safety
-
Controlled fluid drainage – Supports consistent IOP reduction
-
Durable design – Built for lasting performance
Why CE Mark Approval Matters
The CE Mark confirms that the device meets strict European standards for safety and performance. This approval allows MINT® to be used across European markets.
What This Means
-
Proven safety and quality
-
Availability across EU countries
-
Greater trust from doctors and patients
Comparison with Traditional Treatments
Glaucoma is commonly managed using different approaches, each with challenges:
Eye Drops
-
Require daily use and strict compliance
-
May cause irritation or side effects
Laser Therapy
-
Often temporary in effect
-
May need repeat procedures
Traditional Surgery
-
Higher risk of complications
-
Longer recovery time
MINT® Advantages
-
Minimally invasive approach
-
Faster recovery
-
Reduced dependence on medications
-
More consistent pressure control
Clinical Results
Early clinical studies show promising outcomes for the MINT® implant:
-
Significant reduction in intraocular pressure
-
High patient tolerance
-
Fewer side effects compared to traditional methods
-
Improved quality of life with less reliance on eye drops
What’s Next for MINT®?
Following CE approval, Sanoculis is focusing on:
-
Expanding use in European eye clinics
-
Seeking approval in other regions, including the U.S.
-
Enhancing the technology for future improvements
Potential Benefits for Patients
-
Less treatment burden
-
Better long-term disease control
-
More accessible treatment options
Conclusion
The approval of the MINT® Glaucoma Treatment marks an important step forward in eye care. Its minimally invasive design and strong clinical results offer a promising new option for managing glaucoma.
As this technology becomes more widely available, it may help improve outcomes and preserve vision for many patients worldwide.
If you’re considering new glaucoma treatments, consult your eye specialist to learn whether MINT® could be suitable for you.
